South Beach Symposium
South Beach Symposium
February 15, 2017
1 min watch
Save

VIDEO: New IL-17 receptor antagonist for psoriasis near FDA approval

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

MIAMI BEACH, Florida — At South Beach Symposium 2017, Leon Kircik, MD, reported on emerging therapies for the treatment of psoriasis, including new biologics and new pathways.

Editor's note: The FDA announced today, Feb. 16, 2017, that it has approved Siliq (brodalumab, Valeant Pharmaceuticals) as treatment for moderate-to-severe plaque psoriasis.